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Systemic  lupus  erythematosus  (SLE)  and 
Sjögren’s syndrome are related and partly over-
lapping autoimmune diseases that share several 
genetic and phenotypic features. SLE repre-
sents a more severe systemic autoimmune con-
dition, but both diseases may involve multiple 
organs including skin, muscle, joints, and vital 
internal organs such as kidneys. Both disorders 
present with activation of type 1 IFN pathways, 
with increased levels of the cytokines IL-6,   
IL-12/IL-23p40, and TNF- (Borchers et al., 
2003; Ramanujam and Davidson, 2008), and 
both conditions have a genetic association with 
polymorphisms in the IFN regulatory factor 
(IRF) 5 gene (Sigurdsson et al., 2005; Graham 
et al., 2006; Nordmark et al., 2009).
Ro52 is a target autoantigen in several sys-
temic autoimmune diseases, including SLE and 
Sjögren’s syndrome, and molecular characteriza-
tion of Ro52 revealed that it belongs to the TRIM 
(Tripartite motif) family of proteins (Reymond 
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Ro52/Trim21 is targeted as an autoantigen in systemic lupus erythematosus and Sjögren’s 
syndrome. Polymorphisms in the Ro52 gene have been linked to these autoimmune condi-
tions, but the molecular mechanism by which Ro52 may promote development of systemic 
autoimmune diseases has not been explored. To address this issue, we generated Ro52-null 
mice (Ro52/), which appear phenotypically normal if left unmanipulated. However, 
Ro52/ mice develop severe dermatitis extending from the site of tissue injury induced by 
ear tags. The affected mice further develop several signs of systemic lupus with hypergam-
maglobulinemia, autoantibodies to DNA, proteinuria, and kidney pathology. Ro52, which was 
recently identified as an E3 ligase, mediates ubiquitination of several members of the inter-
feron regulatory factor (IRF) family, and the Ro52-deficient mice have an enhanced produc-
tion of proinflammatory cytokines that are regulated by the IRF transcription factors, 
including cytokines involved in the Th17 pathway (interleukin [IL] 6, IL-12/IL-23p40, and 
IL-17). Loss of IL-23/IL-17 by genetic deletion of IL-23/p19 in the Ro52/ mice conferred 
protection from skin disease and systemic autoimmunity. These data reveal that the lupus-
associated Ro52 protein is an important negative regulator of proinflammatory cytokine 
production, and they provide a mechanism by which a defective Ro52 function can lead to 
tissue inflammation and systemic autoimmunity through the IL-23–Th17 pathway.
© 2009 Espinosa et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Ro52 deficiency leads to tissue inflammation  
and systemic autoimmunity
Individual mice are routinely identified either by ear punch-
ing or by metallic ear tags. After ear tagging with metal clips, 
no visible tissue reaction, other than transient erythema and 
swelling, is normally observed. However, 25 wk after appli-
cation of metal ear tags, >90% of Ro52/ mice had devel-
oped a very severe and progressive dermatitis emanating from 
the tagged ear, which did not occur in Ro52+/+ WT litter-
mates (Fig. 2, A-C). Dermatitis also developed in Ro52+/ 
mice but was not present in Ro52-deficient mice that had 
lost  their  ear  tag.  Histological  analysis  of  the  skin  lesions 
showed epidermal hyperplasia with ulcerations and inflam-
matory infiltrates consisting primarily of neutrophils (Fig. 2 B). 
Serum immunoglobulin analysis revealed increased IgG lev-
els in Ro52/ mice with dermatitis (Fig. 2 D), and the af-
fected mice also developed antinuclear antibodies (ANAs), 
with specificity for DNA, and autoantibodies to several lu-
pus-associated autoantigens and other autoantigens (Fig. 2 E 
and Fig. S4). Furthermore, affected mice developed kidney 
pathology with substantiated mesangium and intraglomerular 
immunoglobulin depositions, as well as proteinuria, showing 
impaired renal function (Fig. 2 F). The systemic nature of the 
inflammation was further supported by the development of 
splenomegaly and lymphadenopathy in affected mice (Fig. S4 
and not depicted). Ro52/ mice that were not ear tagged 
did not develop either dermatitis or systemic autoimmunity 
when observed up to 40 wk of age, suggesting that initial tissue 
injury induced by physical ear tagging results in uncontrolled 
tissue inflammation in Ro52/ mice and, subsequently, leads 
to development of systemic autoimmunity.
To elucidate the cellular mechanism causing tissue inflamma-
tion and systemic autoimmunity in Ro52-deficient mice, we an-
alyzed  draining  lymph  node  cells  and  splenocytes  from  the 
affected animals for phenotypic and functional changes. There 
was a marked expansion of CD11b+GR-1+ cells in both spleen 
and lymph nodes, there was an expansion of CD19+ B cells and 
CD3+ T cells in the lymph nodes, and the T cells had attained an 
activated phenotype in the affected mice (Fig. S4). Furthermore, 
lymph node and spleen cells from affected mice hyperproliferated 
spontaneously (not depicted) and produced IL-6, IL-12/ 
IL-23p40, IL-21, IL-22, and IL-17 (Fig. 2, G and H), which was 
further increased upon T cell activation (Fig. 2, G and H). IL-4 
and IFN- production was not increased in the Ro52/ mice 
compared with the Ro52+/+ mice (Fig. 2 H). IL-17 in affected 
mice was produced by CD4+ cells (Fig. 2 I), indicating that Th17 
cells are induced in the Ro52/ mice after skin inflammation. 
The increased production of IL-17 also begins to explain why 
dermal lesions are predominantly composed of neutrophils in the 
Ro52/ mice, as IL-17 recruits and activates these cells.
High levels of proinflammatory cytokines after immune 
activation in Ro52-deficient mice
To further study the hyperresponsive immune system of 
Ro52/ mice in a more controlled manner, we tested the re-
sponse in Ro52/ mice to low doses of the contact-sensitizing 
et al., 2001; Hennig et al., 2005, 2008; Ottosson et al., 2006). 
Like several members of this family, Ro52 has RING-depen-
dent E3 ligase activity (Espinosa et al., 2006) and has been sug-
gested to polyubiquitinate IRF3 and IRF8 (Kong et al., 2007; 
Higgs et al., 2008). Although genetic polymorphisms in the 
Ro52 gene have been linked to the development of SLE and 
Sjögren’s syndrome (Frank et al., 1993; Nakken et al., 2001), 
it has not been addressed how Ro52 regulates cytokine pro-
duction, tissue inflammation, and development of systemic au-
toimmunity. To investigate the molecular mechanisms that 
may link Ro52 to the development of systemic autoimmunity, 
we generated Ro52-deficient GFP-reporter mice.
RESULTS AND DISCUSSION
Ro52 is an immune-specific gene induced by IFNs
We inserted an IRES-GFP reporter cassette into the Ro52 
locus to generate Ro52-deficient mice in which the GFP ex-
pression allowed us to track Ro52-expressing cells in vivo 
(Fig. 1, A–C). Tissue specificity of Ro52 expression has not 
been investigated systematically, and using GFP as a reporter 
for Ro52 expression, we observed that Ro52 was predomi-
nantly expressed in the lymphoid compartments of spleen, 
lymph node, and thymus, with little or no expression in non-
immune tissues including liver, pancreas, heart, kidney, and 
skin (Fig. 1 D and Fig. S1). Some expression was observed in 
endothelial cells (Fig. S1). Our findings are supported by mi-
croarray analysis, showing that Ro52 messenger RNA is pre-
dominantly expressed in lymphoid cell populations in both 
mice and humans (http://biogps.gnf.org). These observations 
suggest that the primary function of Ro52 may be in the im-
mune system. The vast majority of leukocytes in the bone 
marrow, thymus, spleen, lymph nodes, and peripheral blood 
expressed Ro52, as detected by GFP expression, with the high-
est expression in CD3+ and CD11b+GR-1+ cells (Fig. 1 E and 
not depicted). Using GFP as the reporter, we noted that, as has 
previously been reported (Rhodes et al., 2002; Strandberg   
et al., 2008), the expression of Ro52 was induced by IFN- 
and, to a lesser extent, by IFN- and IFN- (Fig. 1 F). Other 
cytokines (TGF- or TNF-) did not affect the expression 
of Ro52 (Fig. 1 F).
Ro52/ mice were born at a slightly reduced Mendelian 
ratio (Ro52+/+, 27%; Ro52+/, 51%; Ro52/, 22%; P = 
0.0001 at n = 280, Chi-Square test) without affecting the 
male/female ratio. However, the Ro52/ mice that were born 
appeared normal and had no detectable abnormalities in or-
gan morphology or histology. Specifically, we did not observe 
any differences in the size or organization in spleen, thymus, 
and lymph nodes or in subsets of immune cells when com-
paring young unmanipulated Ro52+/+, Ro52+/, and Ro52/ 
mice (Figs. S2 and S3). However, splenic CD3+ T cells of 
Ro52/ mice had an increased frequency of T cells with an 
activated phenotype (CD62Llow; Fig. S3). These data indicate 
that although there are discreet signs of early activation in splenic 
T cells in Ro52/ mice, there is no apparent immune phe-
notype or other physical abnormalities present in naive un-
manipulated Ro52-deficient mice.JEM VOL. 206, August 3, 2009  1663
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Figure 1.  Ro52 is expressed in the immune system and induced by IFNs. (A) Targeting construct for generating Ro52/ mice. Primer pairs “a” and 
“b” were used for genotyping WT and targeted allele, respectively. (B) Genotyping PCR for WT (340 bp) and Ro52-null (700 bp) alleles by PCR in Ro52+/+, 
Ro52+/, and Ro52/ mice. (C) Immunoblotting for Ro52 and GFP expression in splenocyte cell extracts demonstrates loss of Ro52 expression and gain 
of GFP expression in Ro52+/ and Ro52/ mice. Data are representative for three independent experiments. (D) Ro52 is specifically expressed in immune 
tissues as shown by GFP expression (brown) in organ sections (five per organ) from Ro52+/ mice investigated by immunohistochemistry using an anti-
GFP antibody. Slides were counterstained with hematoxylin. Data are representative of five independent mice and represent one of two experimental 
repeats. The original magnification was 10×. Bar, 100 µm. (E) Ro52 is expressed in all major leukocyte populations, as shown by GFP expression in Ro52+/ 
splenocytes using flow cytometry. The numbers in the quadrants represent the percentage of cells in each quadrant and are representative of 12 mice 
analyzed in four independent experiments. (F) Ro52 is induced by type I and II IFNs. GFP expression in cells from bone marrow of Ro52+/ mice cultured 
for 24 h with medium (gray line) or medium + cytokine (black line). Filled histogram represents cells from Ro52+/+ mice. Data are representative of three 
independent experiments.1664 Ro52 DEFICIENCY INDUCES SYSTEMIC AUTOIMMUNITY | Espinosa et al.
Figure 2.  Ro52-deficient mice develop tissue inflammation and systemic autoimmunity. (A) Photographs of the progressive dermatitis developing 
spontaneously from tissue injury mediated by ear tags in Ro52-deficient mice. Metal tag length, 1 cm. (B) Histology with Toluidine blue staining of ears of 
tagged Ro52+/+ and Ro52/ mice. Bars, 150 µm. A and B are representative of mice in C. (C) Incidence of dermatitis. 13 independent Ro52/ mice born 
during a period of 1.5 yr and their Ro52+/+ littermates (n = 11) were followed for dermatitis development. Dermatitis developed at different ages but, even-
tually, in all tagged Ro52/ mice, whereas none of their littermate controls developed the disease. (D) Serum immunoglobulin levels determined by ELISA in 
triplicates in Ro52/ mice with dermatitis (n = 6) and Ro52+/+ mice (n = 12; mean± SEM; Mann-Whitney U test). Data represent one of two experimental 
repeats. (E) Ro52/ mice with dermatitis develop ANA. Presence of ANA was tested by immunofluorescence of Hep-2 cells and summarized as the percent 
positive in each group, and anti-DNA antibody levels were measured by ELISA (triplicates) in ANA-positive mice with dermatitis Ro52/ (n = 5) and Ro52+/+ 
(n = 16; Mean± SEM; Mann-Whitney U test). Data represent one of two experimental repeats. Bar, 75 µm. (F, top) Electron microscopy photographs of renal 
glomeruli with increased mesangium and immunoglobulin deposition in Ro52/ mice indicated by arrows. Bar, 2 µm. (F, bottom) Immunofluorescence IgG JEM VOL. 206, August 3, 2009  1665
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and persistent production of cytokines induced by IRF3 and 
5, such as IL-6, TNF-, IFN-, IFN-, and IL-12/IL-23p40. 
To investigate the cytokine production in Ro52/ cells after 
TLR stimulation, the knockout cells were cultured with TLR 
agonists including CpG, LPS, polyI:C, and Imiquimod. The 
stimulation of Ro52/ splenocytes or bone marrow–derived 
macrophages  resulted  in  increased  expression  of  cytokines 
(IL-6, TNF-, IFN-, IFN-, IL-12/IL-23p40, and IL-23p19) 
compared with Ro52+/+ cells (Fig. 4 C and not depicted), 
confirming that the loss of Ro52 indeed leads to increased 
expression of many proinflammatory cytokines. Together, our 
data show that IFNs will induce expression of Ro52 (Fig.1F) 
and that Ro52, in turn, will suppress expression of the pro-
inflammatory cytokines IL-6, TNF-, IFN-, IFN-, and   
IL-12/IL-23p40 through ubiquitination of IRF3, 5, and 8. 
Thus, the cellular role of the IFN-induced Ro52 is to act as a 
negative-feedback regulator of immune responses and inflam-
mation by suppressing the expression of IRF-induced pro-
inflammatory cytokines.
Disruption of the IL-23–Th17 pathway inhibits tissue 
inflammation and systemic autoimmunity in Ro52/ mice
Ro52/ mice developing dermatitis and systemic autoim-
munity produced IL-6 and IL-12/IL-23p40 and had increased 
levels of Th17 cells in the draining lymph nodes. IL-6 and IL-23 
are needed for differentiation and maturation of Th17 cells 
(Cua et al., 2003; Bettelli et al., 2006), and the IL-23–IL-17 
axis appears to be hyperactive in lupus and Sjögren’s syndrome 
(Crispin et al., 2008; Nguyen et al., 2008). We therefore hy-
pothesized that genetic disruption of the IL-23–Th17 path-
way rather than the IL-12–IFN- pathway would result in 
inhibition of the tissue inflammation and systemic autoimmu-
nity in Ro52/ mice. To address this hypothesis, we crossed 
Ro52/ mice with IL-23p19/ mice to disrupt the IL-23–
Th17 pathway. The increased hypersensitivity with dermatitis 
and inflammatory infiltrates observed in Ro52/ mice after 
Oxazolone  application  was  completely  reversed  in  the 
Ro52/ mice lacking IL-23p19 chains (Fig. 5, A and B). 
The enhanced T cell activation observed in Ro52/ mice 
was also reversed in the double knockout mice (Fig. 5 C). In 
addition, the increased expression of IL-23R, IL-12/IL-23p40, 
IL-17, and RoRt in the draining lymph nodes of Ro52/ 
mice was reversed to baseline levels in the Ro52/p19/ 
mice (Fig. 5 D). Furthermore, the skin inflammation after ear 
tagging in the Ro52/ mice did not develop in ear-tagged 
agent Oxazolone. Mice lacking Ro52 had a significantly higher 
contact hypersensitivity to Oxazolone than Ro52+/+ mice, as 
measured by ear thickness (Fig. 3 A), with affected ears showing 
epidermal hyperplasia and inflammatory infiltrates consisting 
predominantly of neutrophils (Fig. 3 B). Analysis of lymphoid 
cell populations in the draining lymph nodes of the Ro52/ 
mice treated with Oxazolone showed accumulation of T cells 
with an activated phenotype (Fig. 3 C) and production of high 
amounts of the proinflammatory cytokines IL-6, IL-12/IL-
23p40, TNF-, and IL-17 and IL-23R expression after appli-
cation of Oxazolone (Fig. 3 D). Production of IFN- was not 
different between WT and Ro52/ mice, and the frequency 
of FoxP3+ cells was not affected (Fig. 3 D). These data demon-
strate that a lack of Ro52 leads to dysregulated tissue inflamma-
tion with enhanced generation of effector T cells that produce 
proinflammatory cytokines.
Ro52 is a negative-feedback regulator of proinflammatory 
cytokine expression
To understand the mechanism by which a deficiency in the 
Ro52 E3 ligase leads to increased cytokine production and tis-
sue inflammation, we aimed to identify substrates ubiquitinated 
by Ro52. IRF8 and IRF3 have been suggested as targets for 
Ro52-mediated ubiquitination (Kong et al., 2007; Higgs et al., 
2008). However, as there is a genetic linkage with IRF5 poly-
morphisms to SLE and Sjögren’s syndrome, and proinflamma-
tory cytokines IL-12/IL-23p40, IL-6, and TNF-, which are 
increased in Ro52/ mice, are also regulated by IRF5, we 
hypothesized that IRF5 may be a substrate for Ro52. Using in 
vivo ubiquitination assays, we confirmed that IRF3 and IRF8 
are polyubiquitinated by Ro52 and, in addition, we observed 
polyubiquitination of IRF5 by Ro52 (Fig. 4 A). SMAD4, 
which has structural homology to the IRF proteins, was used 
as a negative control in our experiments and was not ubiqui-
tinated by Ro52 (Fig. 4 A).
To directly investigate the effects of Ro52 on the tran-
scriptional activity of IRFs, we used a GAL4 one-hybrid lu-
ciferase reporter approach. IRF3 and IRF5 fused to GAL4 
were tested for their ability to drive luciferase expression from 
a 4xGAL4-luciferase reporter plasmid upon transfection into 
293T cells. Cotransfection with Ro52 substantially decreased 
IRF3 and IRF5 transcriptional activity in response to toll-like 
receptor (TLR) 3 or TLR9 signaling induced by polyI:C or 
CpG stimulation (Fig. 4 B). These findings indicate that a de-
ficiency in Ro52 would lead to increased IRF activity in vivo 
staining of renal glomeruli visualizing deposited IgG (red) and proteinuria (g/liter) in mice with dermatitis Ro52/ (n = 7) and age-matched Ro52+/+ mice  
(n = 8; mean± SEM; Mann-Whitney U test). Bar, 10 µm. (G) Increased cytokine expression in draining lymph node cells ex vivo from Ro52/ mice with der-
matitis compared with Ro52+/+ littermates. Cytokine expression was investigated by quantitative RT-PCR in triplicates and calculated relative to HPRT. Data 
are representative for five Ro52/ and five Ro52+/+ mice analyzed in five independent experiments and each assay was performed at least twice. (H) Cyto-
kine production in triplicate supernatants was measured by ELISA after culture of cells from draining lymph nodes with 1 µg/ml anti-CD3 (IFN-, IL-4, and 
IL-17) or 1 µg/ml LPS (IL-12/IL-23p40) for 48 h. Data are representative of one Ro52/ mouse with dermatitis compared with one Ro52+/+ mouse in eight 
independent experiments. Assays were performed at least twice. (I) Cells producing IL-17 were determined by intracellular cytokine staining and flow cytom-
etry of cells from draining lymph nodes after in vitro culture with anti-CD3 for 48 h followed by restimulation with PMA/ionomycin for 4 h. One out of three 
independent experiments is shown. Numbers in quadrants represent the percentage of cells in each.
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(Higgs et al., 2008; Kim and Ozato, 2009). Different func-
tions for Ro52 depending on the degree of cellular activation 
is consistent with our previous observations that Ro52 re-
sides in the cytoplasm in unstimulated cells but translocates 
into the nucleus upon IFN stimulation (Strandberg et al., 2008) 
and that Ro52-mediated ubiquitination is supported both by 
UbcH5 and UbcH6 ubiquitin-conjugating enzymes/E2 ligases 
that are present in the cytoplasm and nucleus, respectively 
(Espinosa et al., 2008). In Ro52/ mice, we observed no 
obvious phenotype in naive unmanipulated mice, but we did 
observe a severe unrelenting tissue inflammation after tissue 
injury, progressing into systemic autoimmunity with several 
lupus-like features, which was dependent on the IL-23–IL-17 
pathway, stressing the importance of Ro52 as a negative reg-
ulator of inflammatory responses. Our data begin to build an 
understanding of how loss or genetic deficiency of Ro52 would 
result in dysregulation of IFN pathways, a feature which is 
common to many systemic autoimmune diseases as they pres-
ent clinically with an “IFN signature” (Baechler et al., 2004; 
Ronnblom et al., 2006). The Ro52 haploinsufficient mice 
developed disease at the same frequency and with similar 
Ro52/p19/ in up to 6 mo (30 wk) of observation (Fig. 5, 
E and F). The Ro52/p19/ mice did not develop ANA or 
anti-DNA antibodies and did not develop kidney pathology 
as did the ear-tagged Ro52/ mice (Fig. 5, G and H). Together, 
these data demonstrate that abrogating the IL-23–Th17 path-
way abolishes tissue inflammation and systemic autoimmunity 
observed in the Ro52-deficient mice after ear tagging and 
Oxazolone treatment.
In summary, our studies demonstrate that Ro52 is a key 
negative regulator of inflammation. Although expressed at a 
steady-state level, Ro52 is further induced by IFNs (Rhodes 
et al., 2002; Strandberg et al., 2008), and our data show that 
Ro52 then acts to control and down-regulate the proinflam-
matory cytokines IL-6, TNF-, IFN-, IFN-, and IL-12/ 
IL-23p40, thus providing a negative-feedback loop by sup-
pressing IFN-mediated immune activation. Recent studies 
indicate dual roles for Ro52 (Kim and Ozato, 2009; Yang et al., 
2009) and indicate that this E3 ligase may act to sustain IRF3 
and IRF8 stability under some conditions but may promote 
polyubiquitination and degradation of the same transcription 
factors after TLR- and IFN-mediated activation of cells 
Figure 3.  Increased tissue inflammation in Ro52/ mice. (A) Increased ear thickness in Ro52/ (n = 5) compared with Ro52+/+ (n = 5) mice after 
Oxazolone challenge. (ANOVA mixed model). (B) Microphotographs of treated ears. Original magnification, 10×. Bars, 100 µm. (C) Flow cytometry analysis 
of draining lymph node cells in mice from A. (D) Cytokines in triplicate supernatants of cultures after in vitro stimulation with 1 µg/ml anti-CD3 of cells 
from draining lymph nodes of five Ro52/ and five Ro52+/+ mice analyzed by ELISA. IL-23R and FoxP3 expression in cells derived from draining lymph 
nodes of five Ro52/ and five Ro52+/+ mice was analyzed by RT-PCR and calculated relative to HPRT. Data in A–D are representative of three indepen-
dent experiments. Error bars represent SEM.JEM VOL. 206, August 3, 2009  1667
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Figure 4.  Ro52 inhibits IRF activity and regulates proinflammatory cytokine expression. (A) Immunoblotting of immunoprecipitates from trans-
fected 293T cells show Ro52-mediated polyubiquitination of IRF3, IRF8, and IRF5 but not SMAD4. FLAG-IRFs and Ro52-GFP were detected in whole cell 
lysates. Data are representative of three independent experiments. Black lines indicate that intervening lanes have been spliced out. (B) The effect of Ro52 
on IRF3 and IRF5 activity was investigated in polyI:C-stimulated TLR3 293T transfectants (IRF3) or CpG-stimulated TLR9 293T transfectants (IRF5) using a 
GAL4 one-hybrid luciferase reporter assay. GAL4-IRF3– and GAL4-IRF5–mediated luciferase expression was diminished by the simultaneous coexpression 
of Ro52 as compared with an empty vector control (EV), indicating that Ro52 inhibits the activity of IRF3 and IRF5. A representative experiment out of 
three independent experiments is shown. RLU, relative luciferase units. (C) Increased proinflammatory cytokine production in splenocytes derived from 
naive Ro52/ (n = 5) compared with Ro52+/+ (n = 5) mice. Splenocytes were cultured with 2 µg/ml CpG and 100 U/ml IFN- or UV-inactivated herpes 
simplex virus (HSV; 2 × 106 PFU/ml), followed by cytokine measures in supernatants (triplicates) by ELISA or DELFIA (IFN- and IFN–). Data are represen-
tative of three independent experiments. Error bars represent SEM.1668 Ro52 DEFICIENCY INDUCES SYSTEMIC AUTOIMMUNITY | Espinosa et al.
Figure 5.  Ro52/ related tissue inflammation is dependent on the IL-23–IL-17 pathway. (A) Ear thickness after Oxazolone challenge. Ro52/p19+/+,  
n = 5; Ro52/p19/, n = 5; p19/Ro52+/+, n = 3; Ro52+/+p19+/+, n = 3 (ANOVA mixed model). (B) Microphotographs of Oxazolone-treated ears. Ears  
of all mice in A were analyzed. Original magnification, 10×. Bars, 100 µm. (C) Flow cytometry analysis of draining lymph node cells of Oxazolone-treated 
mice (Ro52/p19+/+, n = 5; Ro52/p19/, n = 5). (D) Cytokine expression in cells from draining lymph nodes ex vivo measured by RT-PCR with expres-
sion relative to HPRT (Ro52/p19+/+, n = 5; Ro52/p19/, n = 5; Ro52+/+p19+/+, n = 3). Data in A–D depicts one out of two representative experiments. 
Error bars represent SEM. (E) Mice without dermatitis in Ro52/p19+/+ compared with Ro52/p19/ mice. Number of mice observed at different ages 
(Ro52/p19+/+; Ro52/p19/): 5 wk (11; 21), 10 wk (11; 18), 15 wk (11; 14), 20 wk (11; 6), 25 wk (11; 5), and 30 wk (11; 4; Fischer’s exact test). (F) Ear  JEM VOL. 206, August 3, 2009  1669
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Cell isolation and flow cytometry. Single cell suspensions were prepared 
from lymphoid organs and cells blocked in Fc block (BD) for 30 min before 
staining by fluorophore-conjugated antibodies (BD). For intracellular cyto-
kine staining, cells stimulated in vitro with soluble anti-CD3 were restimu-
lated for 4 h with 50 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin 
(Sigma-Aldrich), and 1 µl/ml GolgiStop (BD), followed by surface marker 
and intracellular cytokine staining according to the manufacturer’s instruc-
tions. Cells were analyzed on a flow cytometer (BD).
Serologic  and  proteinuria  analyses.  Immunoglobulin  isotype  serum 
leves were analyzed using the SBA Clonotyping System/AP kit (Southern-
Biotech), ANA by Hep-2 slides (Immuno Concepts), and anti-DNA anti-
bodies, as previously described (Wermeling et al., 2007), in ELISA using 
plates coated with methylated bovine serum albumin and activated calf thy-
mus DNA (Sigma-Aldrich). Lupus autoantigen microarrays were generated 
and used, as previously described, with 41 autoantigens spotted in replicates 
of six (Wu et al., 2008). Sera were diluted 1:50–1:100 in the assays. Protein-
uria was detected using Multistix 5 (Bayer).
Cytokine analysis by ELISA and quantitative RT-PCR. Culture su-
pernatants were collected after stimulation, as defined in each experiment, to 
assess cytokine production by ELISA or cytometric bead array (R&D Sys-
tems; BD). IFN- was quantified by dissociation-enhanced lanthanide fluo-
roimmunoassay as previously described (Strandberg et al., 2008). RNA was 
extracted with RNeasy columns (QIAGEN) from cells ex vivo and analyzed 
by quantitative RT-PCR according to the manufacturer’s instructions (Ap-
plied Biosystems) and expression related to HPRT.
Oxazolone  provocation.  Oxazolone  (4-ethozymethylene-2-phenyl-2-
oxazolin-5-one) provocation was performed using the ear swelling test as 
described in Yokozeki et al. (2000). Mice were sensitized on shaved back 
skin with 150 µl of 0.3% Oxazolone (Sigma-Aldrich) dissolved in acetone/
olive oil (4:1) applied on two consecutive days. 5 d later, the ears were chal-
lenged with 50 µl of a 0.1% Oxazolone solution on one ear and with the ve-
hicle on the other. This was repeated on three consecutive days, and ear 
swelling was measured by a micrometer (Kroeplin). The whole procedure 
was repeated up to four times. Change in thickness was calculated by sub-
tracting swelling caused by the vehicle.
Ubiquitination assays. 293T cells were transfected with 500 ng FLAG-
IRF or FLAG-SMAD4, 500 ng Ro52-GFP, and 500 ng Myc-ubiquitin. 
The SMAD4 plasmid was a gift from C.-H. Heldin (Uppsala University, 
Uppsala, Sweden). 10 µM MG132 was added 28 h after transfection and cells 
were harvested 6 h later. Cells were lysed in immunoprecipitation buffer 
and, after clearing of the lysate, FLAG-M2-agarose beads (Sigma-Aldrich) 
were added, followed by incubation for 2 h. After washing, FLAG-IRFs 
were eluted with FLAG peptide (Sigma-Aldrich) and separated by SDS-
PAGE, and ubiquitinated FLAG-IRFs were detected by immunoblotting 
against Myc (Santa Cruz Biotechnology, Inc.). FLAG-IRFs and GFP-Ro52 
were  detected  in  whole  cell  lysates  by  immunoblotting  against  FLAG 
(Sigma-Aldrich) and GFP (Sigma-Aldrich).
Luciferase assays. For measurement of IRF activity, 105 293T cells were 
transfected in triplicates in 24-well plates using Fugene HD (Roche). Each 
well was transfected with 20 ng GAL4-IRF, 20 ng MycRo52 or empty Myc 
vector, 20 ng pRL-TK-Renilla, 20 ng pcDNA3.1-TLR9 or pFLAG-CMV1-
TLR3 (gift from R. Medzhitov, Yale University, New Haven, CT; plasmids 
13084 and 13091, respectively; Addgene), and 50 ng GAL4 reporter plasmid 
MH100-luc. After 16 h, cells were harvested and prepared for the reporter 
phenotypical expression as the mice that completely lacked 
Ro52, suggesting an important role of Ro52 in regulating 
immune homeostasis and that even a partial loss of function 
for this key regulatory protein would result in exaggerated tissue 
inflammation and systemic autoimmunity. From our data, 
one would predict that the human genetic linkage to poly-
morphisms in the Ro52 gene most likely relate to reduction 
in the level, binding, or function of Ro52 in systemic auto-
immune patients.
Although the role of IL-17 and the Th17 pathway in lupus 
and Sjögren’s syndrome is only beginning to be explored, sev-
eral studies implicate a role for Th17 effector cells also in these 
autoimmune conditions (Crispin et al., 2008; Nguyen et al., 
2008; Sakai et al., 2008; Wong et al., 2008). Furthermore, our 
data suggest that loss of IL-17 also suppresses development of 
exaggerated skin inflammation in Ro52/ animals. Together, 
the present data link Ro52, an E3 ligase which targets many 
transcription factors in the IFN pathway, to disregulated pro-
inflammatory cytokine production and to the development of 
tissue specific inflammation and systemic autoimmunity.
Materials and Methods
Generation of Ro52/ mice. Ro52/ mice were generated using stan-
dard gene targeting techniques. In brief, a short (1.7 kb) and a long (5 kb) 
arm were PCR cloned from the C57BL/6J BAC clone RP23-311N6 using 
the following primers: short arm, forward, 5-ATCGATTGCAGAGGCA-
AAGCCATGGGAAAG-3, and reverse, 5-ATCGATTCCTCCTCTCC-
AGCTCTGAGATCA-3; and long arm, forward, 5-GTCGACAGGC-
TACAACAGCTGTGCTCAGA-3, and reverse, 5-GCGGCCGCACC-
CTGGCCTTGATTTCTAACAG-3. They were then ligated into the gene 
targeting cassette vector pKS-TK-NeoloxP-IRES-GFP. The C57BL/6- 
derived embryonic stem cell line V26.2 was used for homologous recombi-
nation, and targeted embryonic stem cell clones were identified by Southern 
blotting and injected into BALB/c embryos. Chimeras carrying the target 
allele were bred to C57BL/6J mice. Ro52/p19/ mice were generated 
by intercrossing Ro52/ and p19/ mice obtained from the Mutant mouse 
Regional Resource Center (www.mmrrc.org). The study was approved by 
the Ethical Review Committee North, Stockholm County and Standing 
Committee on Animals at Harvard Medical School.
Histochemistry and electron microscopy. Organs were fixed in 4% 
paraformaldehyde  for  24  h,  embedded  in  paraffin,  and  4–5-µm  sections 
stained with hematoxylin/eosin or Toluidine blue or were used in immuno-
histochemistry with rabbit polyclonal anti-GFP (Invitrogen), rat monoclonal 
anti-CD3 (clone SP7; Thermo Fisher Scientific), or rat monoclonal anti-
B220 (clone RA3-6B2; BD). Antigen retrieval was performed using Re-
triever 2100 (PickCell Laboratories). For electron microscopy, small pieces 
of kidneys were further fixed in 2.5% glutaraldehyde and postfixed in 1% 
OsO4 plus 1% potassium ferrocyanide, followed by staining with 0.5% ura-
nyl acetate. After dehydration, specimens were embedded in epoxy resin 
(agar 100) and cured by heat. 50-nm sections were contrasted with lead ci-
trate and uranyl acetate and examined with an electron microscope (912AB; 
Carl Zeiss, Inc.) equipped with a MegaView III camera (Olympus) for digi-
tal image capture. Immunofluorescence staining of kidneys was performed 
on 7-µm paraformaldehyde-fixed sections of snap-frozen organs with an Al-
exa Flour 594–conjugated donkey anti–mouse IgG (Invitrogen).
with tag in Ro52/p19/ mouse showing no inflammation or dermatitis. Data are representative of mice in E. Metal tag length, 1 cm. (G) ANA analysis 
tested by immunofluorescence of Hep-2 cells and summarized as the percent positive in each group, and anti-DNA antibody levels measured by ELISA (trip-
licates) in Ro52/ p19+/+ (n = 7), Ro52/p19/ (n = 10), and Ro52+/+p19+/+ (n = 7; mean ± SEM; Mann-Whitney U test). Bar, 50 µm. (H) Electron micros-
copy image of kidneys depicting reversal of pathological changes in Ro52/p19/ mice (arrows). All mice in A were analyzed. Bar, 2 µm.
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assay (Dual-Luciferase Reporter Assay system; Promega). Firefly luciferase 
luminescence was normalized to Renilla luminescence and used as a measure 
of IRF activity. Results are shown relative to transfections in which GAL4 
was not fused to any IRF.
Statistical analysis. Data are expressed as mean ± SEM. Analysis of non-
parametric data between groups was performed with a Mann-Whitney U 
test. Analysis, including repeated measures, was performed with an ANOVA 
mixed model, and a Fischer’s exact test was used for analysis of frequencies 
between groups in small samples.
Online supplemental material. Fig. S1 shows expression of GFP as a 
reporter for Ro52. Fig. S2 shows lymphoid organization in Ro52+/+, Ro52+/, 
and Ro52/ mice. Fig. S3 shows leukocyte cell populations in naive mice.   
Fig. S4 shows autoantibody reactivity and splenomegaly in Ro52/ mice.   
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20090585/DC1.
We thank Nora Ramirez, Vijole Dzikaite, and Ann Trönnberg for skillful technical 
assistance, Mohamed Oukka for targeting vector design, Henrik Källberg for 
statistical analyses, and Professor Carl-Henrik Heldin (Uppsala University, Uppsala, 
Sweden) for the gift of the SMAD4 plasmid.
This work was supported by grants from the Swedish Research Council, the 
Swedish Foundation for Strategic Research, the Stockholm County Council, King 
Gustaf the Vth 80-year foundation, the Göran Gustafsson Foundation, the Torsten 
and Ragnar Söderberg Foundation, the Heart-Lung Foundation, Science Foundation 
Ireland, and the Swedish Rheumatism Association.
The authors have no conflicting financial interests.
submitted: 16 March 2009
accepted: 22 June 2009
REFERENCES
Baechler, E.C., P.K. Gregersen, and T.W. Behrens. 2004. The emerging role 
of interferon in human systemic lupus erythematosus. Curr. Opin. Immunol. 
16:801–807. 
Bettelli, E., Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, 
and  V.K.  Kuchroo.  2006.  Reciprocal  developmental  pathways  for  the 
generation of pathogenic effector TH17 and regulatory T cells. Nature. 
441:235–238. 
Borchers,  A.T.,  S.M.  Naguwa,  C.L.  Keen,  and  M.E.  Gershwin.  2003. 
Immunopathogenesis of Sjogren’s syndrome. Clin. Rev. Allergy Immunol. 
25:89–104. 
Crispin, J.C., M. Oukka, G. Bayliss, R.A. Cohen, C.A. Van Beek, I.E. 
Stillman, V.C. Kyttaris, Y.T. Juang, and G.C. Tsokos. 2008. Expanded 
double negative T cells in patients with systemic lupus erythematosus 
produce IL-17 and infiltrate the kidneys. J. Immunol. 181:8761–8766.
Cua, D.J., J. Sherlock, Y. Chen, C.A. Murphy, B. Joyce, B. Seymour, L. 
Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 
rather than interleukin-12 is the critical cytokine for autoimmune in-
flammation of the brain. Nature. 421:744–748. 
Espinosa, A., W. Zhou, M. Ek, M. Hedlund, S. Brauner, K. Popovic, 
L. Horvath, T. Wallerskog, M. Oukka, F. Nyberg, et al. 2006. The 
Sjogren’s syndrome-associated autoantigen Ro52 is an E3 ligase that 
regulates proliferation and cell death. J. Immunol. 176:6277–6285.
Espinosa, A., V. Oke, A. Elfving, F. Nyberg, R. Covacu, and M. Wahren-
Herlenius. 2008. The autoantigen Ro52 is an E3 ligase resident in the 
cytoplasm but enters the nucleus upon cellular exposure to nitric oxide. 
Exp. Cell Res. 314:3605–3613. 
Frank, M.B., K. Itoh, A. Fujisaku, P. Pontarotti, M.G. Mattei, and B.R. 
Neas. 1993. The mapping of the human 52-kD Ro/SSA autoantigen 
gene to human chromosome 11, and its polymorphisms. Am. J. Hum. 
Genet. 52:183–191.
Graham, R.R., S.V. Kozyrev, E.C. Baechler, M.V. Reddy, R.M. Plenge, 
J.W. Bauer, W.A. Ortmann, T. Koeuth, M.F. Gonzalez Escribano, B. 
Pons-Estel, et al. 2006. A common haplotype of interferon regulatory 
factor 5 (IRF5) regulates splicing and expression and is associated with 
increased risk of systemic lupus erythematosus. Nat. Genet. 38:550–555. JEM VOL. 206, August 3, 2009  1671
BRIEF DEFINITIVE REPORT
Wong, C.K., L.C. Lit, L.S. Tam, E.K. Li, P.T. Wong, and C.W. Lam. 
2008. Hyperproduction of IL-23 and IL-17 in patients with systemic 
lupus erythematosus: implications for Th17-mediated inflammation in 
auto-immunity. Clin. Immunol. 127:385–393. 
Wu, H.Y., F.J. Quintana, and H.L. Weiner. 2008. Nasal anti-CD3 antibody 
ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ 
regulatory T cell and is associated with down-regulation of IL-17+ CD4+ 
ICOS+ CXCR5+ follicular helper T cells. J. Immunol. 181:6038–6050.
Yang, K., H.X. Shi, X.Y. Liu, Y.F. Shan, B. Wei, S. Chen, and C. Wang. 
2009. TRIM21 is essential to sustain IFN regulatory factor 3 activation 
during antiviral response. J. Immunol. 182:3782–3792. 
Yokozeki, H., M. Ghoreishi, S. Takagawa, K. Takayama, T. Satoh, I. Katayama, 
K. Takeda, S. Akira, and K. Nishioka. 2000. Signal transducer and acti-
vator of transcription 6 is essential in the induction of contact hypersen-
sitivity. J. Exp. Med. 191:995–1004. 